Source:http://linkedlifedata.com/resource/pubmed/id/18000164
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2008-2-11
|
pubmed:abstractText |
Megakaryocytes and platelets express the Gs-coupled VPAC1 receptor, for which the pituitary adenylyl cyclase-activating peptide (PACAP) and the vasointestinal peptide (VIP) are agonists. We here demonstrate a regulatory role for VPAC1 signaling during megakaryopoiesis. A total of 2 patients with trisomy 18p with PACAP overexpression and transgenic mice overexpressing PACAP in megakaryocytes have thrombopathy, a mild thrombocytopenia, and a reduced number of mature megakaryocytes in their bone marrow. In vitro differentiation of hematopoietic stem cells from the patient and transgenic mice shows a reduced number of megakaryocyte colonies compared with controls. The addition of PACAP, VIP, or the adenylyl cyclase activator forskolin to CD34(+) cells inhibits megakaryocyte differentiation. In contrast, neutralizing monoclonal anti-PACAP (PP1A4) or anti-VPAC1 (23A11) antibodies inhibit cAMP formation and stimulate megakaryopoiesis in a thrombopoietin-independent manner. Moreover, wild-type mice obtain an increased platelet count after subcutaneous injection of PP1A4 or 23A11. These antibodies also elevate platelet numbers in animal models of myelosuppressive therapy and in GATA1-deficient mice with congenital thrombocytopenia. Furthermore, 23A11 stimulates the in vitro megakaryocyte differentiation of both normal and GATA1-deficient human CD34(+) cells. Together, our data strongly suggest that VPAC1 signaling tempers normal megakaryopoiesis, and that inhibition of this pathway stimulates megakaryocyte differentiation, enhancing platelet recovery after myelosuppressive therapy and in GATA1 deficiency.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ADCYAP1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Pituitary Adenylate...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasoactive Intestinal...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
111
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1885-93
|
pubmed:meshHeading |
pubmed-meshheading:18000164-Animals,
pubmed-meshheading:18000164-Animals, Genetically Modified,
pubmed-meshheading:18000164-Antigens, CD,
pubmed-meshheading:18000164-Antigens, CD34,
pubmed-meshheading:18000164-Cell Line, Tumor,
pubmed-meshheading:18000164-Chromosomes, Human, Pair 18,
pubmed-meshheading:18000164-Cyclic AMP,
pubmed-meshheading:18000164-Humans,
pubmed-meshheading:18000164-Megakaryocytes,
pubmed-meshheading:18000164-Mice,
pubmed-meshheading:18000164-Mice, Transgenic,
pubmed-meshheading:18000164-Pituitary Adenylate Cyclase-Activating Polypeptide,
pubmed-meshheading:18000164-Rabbits,
pubmed-meshheading:18000164-Receptors, Vasoactive Intestinal Polypeptide, Type I,
pubmed-meshheading:18000164-Thrombocytopenia,
pubmed-meshheading:18000164-Trisomy
|
pubmed:year |
2008
|
pubmed:articleTitle |
PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications.
|
pubmed:affiliation |
Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. kathleen.freson@med.kuleuven.be
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|